HALLETT DAVID (Chief Scientific Officer) received a stock award from RECURSION PHARMACEUTICALS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 2 awards
Filed: 2/10/2026ACC: 0001601830-26-000012
Officer· Chief Scientific Officer
Since Feb 2026
+514.92K
Net shares
Net buyer
$45.4K
Total sold
0
Open market trades
0B · 0S
3
Total transactions
526.32K acquired · 11.40K disposed
Non-Derivative Transactions3
Class A Common Stock
Direct
Shares
+502.06K
Price / share
—
Trade value
—
% of position
84.5%
2/6/2026
594.14K→1.10M
Class A Common Stock
Direct
Shares
+24.25K
Price / share
—
Trade value
—
% of position
2.2%
2/6/2026
1.10M→1.12M
Class A Common Stock
Direct
Shares
−11.40K
Price / share
$3.98
Trade value
$45.37K
% of position
1.0%
2/6/2026
1.12M→1.11M
Total
Net shares
+514.92K
Net value
-$45.37K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock Direct | 2/6/2026 | A · Award | +502.06K | — | — | 84.5% | 594.14K | 1.10M |
| Class A Common Stock Direct | 2/6/2026 | A · Award | +24.25K | — | — | 2.2% | 1.10M | 1.12M |
| Class A Common Stock Direct | 2/6/2026 | F · Tax Withholding | −11.40K | $3.98 | $45.37K | 1.0% | 1.12M | 1.11M |
| Total | +514.92K | -$45.37K | ||||||
Derivative Transactions0
No derivative transactions reported